Phaseline

Companies › Zai Lab (Shanghai)

Zai Lab (Shanghai): clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 3; Oncology, Ophthalmology, Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZL-1109 (VRDN-003)
IGF-1 receptor antagonist
IGF1RPhase 3Thyroid Eye Disease (TED)Mar 2027
ZL-1310–Phase 3Small-cell Lung Cancer; SCLC; Solid TumorsMay 2027
ZL-1503–Phase 1Atopic Dermatitis (AD)Dec 2027
ZL-6201–Phase 1Solid TumorsAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07211776ZL-1109 (VRDN-003)Phase 3Thyroid Eye Disease (TED)OphthalmologyMar 2027
NCT06179069ZL-1310Phase 1SCLCOncologyMay 2027
NCT06885281ZL-1310Phase 1Solid TumorsOncologyAug 2027
NCT07235384ZL-1503Phase 1Atopic Dermatitis (AD)ImmunologyDec 2027
NCT07218146ZL-1310Phase 3Small-cell Lung CancerOncologyJun 2028
NCT07374848ZL-6201Phase 1Solid TumorsOncologyAug 2028

From the company's SEC filings

Cash and short-term investments of $560m on 2026-09-30; operating cash outflow about $179m a year; runway about 38 months at that burn, to Nov 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IGF1R (1)

Companies with the same targets

Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics

Companies built like this

Minghui Pharmaceutical (Hangzhou) Corvus Pharmaceuticals Nuvation Bio Ascentage Pharma Group Sellas Life Sciences Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.